FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma By Ogkologos - January 10, 2025 761 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment in Patients with MIBC and Response Can Be Monitored by ctDNA New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation MOST POPULAR Veteran Avoided The Barber For 6 Years After He Left The... February 28, 2020 FDA Recognises OncoKB Database of Molecular Tumour Marker Information October 8, 2021 Adding Pembrolizumab to Platinum-Based Chemotherapy Improves Survival in Patients with Previously... June 23, 2023 EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept January 15, 2026 Load more HOT NEWS Embedding research integrity at the core of our science Treating the Whole Person: How Cancer Centers Are Addressing Social Needs Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations Can Age Affect Response to Immune Checkpoint Inhibitors?
